AEGIS-II
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
- Stage
- klaar
- Medicine
- CSL112
- Population
- ASCVD
- Phase
- III
- First Patient In
- 31 December 2018
- Last Patient In
- 18 November 2022
- Last Patient Last Visit
- 17 November 2023
National Lead
prof. dr. J.H. Cornel
Cardioloog
Study Director
drs. B.J.B. Hamer
Cardioloog
Office Contact
